Company news

Shanghai Shyndec Pharmaceutical Co., Ltd. news in 2026

Shanghai Shyndec Pharmaceutical Co., Ltd.'s news releases, calls and decks from 2026, newest first.

View company

(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate by Wholly-owned Subsidiary

November 13, 2026

(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Controlled Subsidiary Passing the Drug GMP Compliance Inspection

November 9, 2026

(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Withdrawal of Drug Registration Application by Controlled Subsidiary

November 5, 2026

(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate by Wholly-owned Subsidiary

November 5, 2026

(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Attending the Q3 2026 Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction

November 4, 2026

(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Report for Q3 2026

October 30, 2026

(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Resolutions of the 9th Meeting of the 9th Board of Directors

October 30, 2026

(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Departure of Director and By-election of Director

October 30, 2026

(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Progress of Signing of the Drug Marketing Authorization Transfer Contract by Controlled Subsidiary

October 22, 2026

(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate

October 22, 2026

(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate

October 15, 2026

(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Performance Forecast for the First Three Quarters of 2026

October 14, 2026

(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate

September 29, 2026

Announcement on Progress of Provision of Guarantees by a Wholly-owned Subsidiary to Its Subordinate Enterprise

September 11, 2026

Announcement on Implementation of Dividend Distribution for the First Half of 2026

September 10, 2026

Announcement on Convening the 2026 Semi-annual Performance Briefing

September 2, 2026

Announcement on the Wholly-Owned Subsidiary's Receipt of the Approval Notice for the Marketing Application of a Chemical API

August 27, 2026

Announcement on Resolutions of the 8th Meeting of the 9th Board of Directors

August 26, 2026

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

August 19, 2026

Announcement on Wholly-owned Sub-subsidiary Obtaining Approval for Marketing of Chemical APIs

August 4, 2026

Announcement on Resolutions of the 6th Meeting of the 9th Board of Directors

August 3, 2026

Announcement on Progress of Signing of the "Drug Marketing Authorization Transfer Contract" by a Controlled Subsidiary

July 30, 2026

Announcement on Obtaining Drug Registration Certificate by Wholly-owned Subsidiary

July 24, 2026

Announcement on Obtaining Drug Registration Certificate

July 23, 2026

Announcement on the Wholly-owned Subsidiary's Drug Passing Generic Drug Consistency Evaluation

July 13, 2026

Semi-annual Performance Forecast for 2026

July 10, 2026

Announcement on Resolutions of the 5th Meeting of the 9th Board of Directors

June 30, 2026

Announcement on Holding Subsidiary Obtaining Drug Registration Certificate

June 25, 2026

Announcement on Obtaining Drug Registration Certificate by Subsidiary

June 23, 2026

Announcement on Implementation of Dividend Distribution for 2025

May 25, 2026

Announcement on Obtaining Drug Registration Certificate

May 21, 2026

Announcement on Wholly-owned Subsidiary's Drug Substance Obtaining Indian Registration Certificate

May 11, 2026

Announcement on Resolutions of the 2025 Annual General Meeting

May 8, 2026

Report for Q1 2026

April 29, 2026

Announcement on Progress in Providing Guarantees for Subsidiaries

April 15, 2026

Earnings Preannouncement for Q1 2026

April 10, 2026

Announcement on Voluntary Information Disclosure of Wholly-owned Subsidiary's Drug Passing Consistency Evaluation for Generic Drugs

April 3, 2026

Announcement on Estimated Daily Related Party Transactions in 2026

March 27, 2026

by Holding Subsidiary

March 24, 2026

Announcement on Obtaining Drug Registration Certificate by Wholly-owned Subsidiary

March 3, 2026

Announcement on Wholly-owned Sub-subsidiary Obtaining Approval for Marketing of Chemical APIs

February 24, 2026

Announcement on Proposed Selection of Partial Drugs for Continuation Procurement Under National Procurement Scheme After Agreement Expiry

February 11, 2026

Announcement on Wholly-owned Subsidiary's Passing GMP Compliance Inspection for Drugs

February 9, 2026

Announcement on Provision for Impairment

January 26, 2026